The Medical Letter on Drugs and Therapeutics
Brimonidine Gel (Mirvaso) for Rosacea
October 14, 2013 (Issue: 1427)The FDA has approved the selective alpha2-adrenergic receptor agonist brimonidine as a 0.33% gel (Mirvaso – Galderma) for topical treatment of adults with persistent facial erythema of rosacea. Brimonidine is also available in ophthalmic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.